Scandion has applied for and received approval for admission to trading on Nasdaq First North. The first day of trading in the Company’s share on Nasdaq First North is 3 February 2021. Trading in the Company’s share on Spotlight Stock Market will end and the last day of trading on Spotlight Stock Market is 2 February 2021.

Nasdaq’s decision is conditional upon (i) that nothing occurs in connection with the change of listing venue that could lead to a different assessment by Nasdaq, and (ii) that the Company, no later than two days before the first day of trading, updates its website in accordance with Nasdaq First North Growth Market Rulebook.

CEO Bo Rode Hansen comments:

"I am pleased that Scandion Oncology is being welcomed on Nasdaq First North in our journey towards making a difference for patients suffering with resistant tumours. This change in listing venue comes as a natural result of our plan to internationalise Scandion Oncology by offering our share to the many international investors trading on the Nasdaq platforms. I would like to thank Spotlight Stock Market and I look forward to welcoming new and existing shareholders to this part of our journey."

Scandion’s stock will continue to be traded under the ticker SCOL with ISIN code DK0061031895. No new shares will be issued in connection with the Company’s shares being admitted to trading on Nasdaq First North and the Company’s shareholders do not need to take any actions in connection with the change of listing venue.

Additional information

Scandion has prepared a supplementary document that is available on the Company’s website, www.scandiononcology.com. The supplementary document shall be read as a supplement to the prospectus that the Company published in connection with the rights issue of shares that was resolved on by the board of directors of Scandion on 16 November 2020. The supplementary document is not a prospectus, has not been reviewed or approved by any regulatory authority and does not contain an offer of shares or other financial instruments.

Certified Adviser

Scandion has appointed Västra Hamnen Corporate Finance AB as the Company’s Certified Adviser on Nasdaq First North.

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

For further information, please contact:

Bo Rode Hansen, CEO

Phone: +45 38 10 20 17

E-mail: info@scandiononcology.com

The information was provided by the contact person above for publication on 19 January 2021.

About Scandion Oncology

Scandion Oncology A/S is a clinical stage II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The company is targeting cancer drug resistance in various treatment modalities including, chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. Ticker code: SCOL. The Company is conducting a list change from Spotlight Stock Market to Nasdaq First North Growth Market Sweden in February 2021.